ASPIRIN AND DIPYRIDAMOLE Drug Patent Profile

Which patents cover Aspirin And Dipyridamole, and what generic alternatives are available?

Aspirin And Dipyridamole is a drug marketed by Amneal Pharms, Ani Pharms, Barr, Chartwell Molecular, Dr Reddys, Glenmark Speclt, Micro Labs, Ph Health, Sandoz, Sun Pharm, and Zydus Pharms. and is included in eleven NDAs.

The generic ingredient in ASPIRIN AND DIPYRIDAMOLE is aspirin; dipyridamole. There are twenty-two drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the aspirin; dipyridamole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aspirin And Dipyridamole

A generic version of ASPIRIN AND DIPYRIDAMOLE was approved as aspirin; dipyridamole by BARR on August 14^th, 2009.

Summary for ASPIRIN AND DIPYRIDAMOLE

US Patents:	0
Applicants:	11
NDAs:	11
Finished Product Suppliers / Packagers:	9
Clinical Trials:	25
What excipients (inactive ingredients) are in ASPIRIN AND DIPYRIDAMOLE?	ASPIRIN AND DIPYRIDAMOLE excipients list
DailyMed Link:	ASPIRIN AND DIPYRIDAMOLE at DailyMed

Recent Clinical Trials for ASPIRIN AND DIPYRIDAMOLE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rutgers, The State University of New Jersey	Phase 3
Ministry of Health, France	Phase 3
University Hospital, Lille	Phase 3

See all ASPIRIN AND DIPYRIDAMOLE clinical trials

Pharmacology for ASPIRIN AND DIPYRIDAMOLE

Drug Class	Nonsteroidal Anti-inflammatory Drug Platelet Aggregation Inhibitor
Mechanism of Action	Cyclooxygenase Inhibitors
Physiological Effect	Decreased Platelet Aggregation Decreased Prostaglandin Production

US Patents and Regulatory Information for ASPIRIN AND DIPYRIDAMOLE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal Pharms	ASPIRIN AND DIPYRIDAMOLE	aspirin; dipyridamole	CAPSULE, EXTENDED RELEASE;ORAL	206392-001	Mar 8, 2016	AB	RX	No	No
Micro Labs	ASPIRIN AND DIPYRIDAMOLE	aspirin; dipyridamole	CAPSULE, EXTENDED RELEASE;ORAL	209929-001	Aug 11, 2021	AB	RX	No	No
Chartwell Molecular	ASPIRIN AND DIPYRIDAMOLE	aspirin; dipyridamole	CAPSULE, EXTENDED RELEASE;ORAL	204552-001	Mar 20, 2019		DISCN	No	No
Ph Health	ASPIRIN AND DIPYRIDAMOLE	aspirin; dipyridamole	CAPSULE, EXTENDED RELEASE;ORAL	207944-001	Jan 18, 2017	AB	RX	No	No
Ani Pharms	ASPIRIN AND DIPYRIDAMOLE	aspirin; dipyridamole	CAPSULE, EXTENDED RELEASE;ORAL	206964-001	Jan 18, 2017		DISCN	No	No
Barr	ASPIRIN AND DIPYRIDAMOLE	aspirin; dipyridamole	CAPSULE, EXTENDED RELEASE;ORAL	078804-001	Aug 14, 2009	AB	RX	No	No
Glenmark Speclt	ASPIRIN AND DIPYRIDAMOLE	aspirin; dipyridamole	CAPSULE, EXTENDED RELEASE;ORAL	210318-001	May 24, 2019	AB	RX	No	Yes

Market Dynamics and Financial Trajectory for Aspirin and Dipyridamole

Last updated: February 28, 2026

What is the current market size for aspirin and dipyridamole?

The global market for aspirin was valued at approximately USD 2.3 billion in 2021 and is projected to reach USD 3.2 billion by 2028, growing at a compound annual growth rate (CAGR) of 4.7%.[1] Dipyridamole, primarily used as an adjunct in stroke prevention and imaging procedures, had a smaller market valuation estimated at USD 150 million in 2021. Its growth is driven by increased stroke prevalence and expanded indications.

How does the regulatory landscape impact market growth?

Aspirin's over-the-counter (OTC) status in many regions simplifies consumer access, supporting steady volume sales. However, regulatory scrutiny on specific formulations occurs, especially regarding cardiovascular indications. In the US, the FDA regularly reviews claims and formulations to ensure safety. Dipyridamole faces less regulatory restriction but requires prescription approval for many indications, limiting its market scope.

What are the key factors influencing market supply and demand?

Supply chain considerations for aspirin are stable, with multiple global manufacturing sites. Demand is driven by primary and secondary cardiovascular disease prevention, with notable growth among aging populations. Dipyridamole's demand correlates with stroke management protocols and advances in imaging techniques that utilize the drug’s vasodilatory properties. Off-label uses contribute to demand variability.

Which market players dominate the space?

Major pharmaceutical companies like Bayer, Johnson & Johnson, and Sanofi dominate the aspirin market with established OTC and prescription portfolios. For dipyridamole, companies such as Boehringer Ingelheim and AstraZeneca maintain significant market share, often through licensing agreements and regional manufacturing.

Are there recent innovation trends affecting these drugs?

Innovations in aspirin formulations, including delayed-release and low-dose variants, improve safety profiles and patient adherence. There is ongoing research into combination therapies incorporating aspirin with other antiplatelet agents. Dipyridamole development centers on enhancing bioavailability and expanding indications, including potential use in neuroprotective research.

How are pricing strategies evolving?

Aspirin's over-the-counter status maintains a competitive, low-price environment. Generic versions dominate, exerting downward pressure on prices. Patent expirations have further increased price competition. Dipyridamole’s patented formulations remain premium-priced, but generic versions are growing. Price pressures influence profit margins across manufacturers.

What are the major growth barriers?

Risks include adverse effects associated with long-term aspirin use, such as bleeding, which can limit patient adherence. The availability of alternative antiplatelet agents like clopidogrel and newer therapies limits aspirin’s growth in certain indications. For dipyridamole, limited indications and competition from other stroke prevention drugs constrain expansion.

How does the competitive landscape influence future projections?

Consolidation among pharmaceutical firms, driven by licensing and acquisition strategies, shapes market dynamics. Patent cliffs for branded formulations increase generic competition. Strategic partnerships focusing on new delivery mechanisms and combination therapies may foster growth opportunities.

What are the projected financial trajectories?

Aspirin's market is expected to grow at a CAGR of 4.5–5% through 2028, supported by aging demographics and cardiovascular disease prevalence. Dipyridamole's market is projected to grow more slowly, at approximately 2–3% CAGR, influenced by regulatory approvals for new indications and ongoing research. Revenue shifts favor generic manufacturers, which account for over 70% of aspirin sales as of 2022.[2]

---

Key Takeaways

• Aspirin’s global market size was USD 2.3 billion in 2021; growth driven by cardiovascular disease prevalence, aging populations, and generic competition.
• Dipyridamole’s market remains niche, valued at USD 150 million in 2021, with growth opportunities linked to stroke prevention and imaging protocol advancements.
• Regulatory frameworks favor OTC aspirin sales but impose limitations on specific formulations; dipyridamole's prescription status limits its demand scope.
• Innovation focuses on formulation improvements and expanding indications; price pressures benefit generic manufacturers.
• Future growth hinges on competitive dynamics, patent expirations, and research into new therapeutic uses.

---

FAQs

What factors most influence aspirin’s market share?
Availability of generics, regulatory approval, cardiovascular disease prevalence, and consumer preferences for OTC medications.

How does dipyridamole compare to newer stroke prevention drugs?
It has a narrower use case, mainly as an adjunct, with newer agents offering simplified regimens and better safety profiles.

What regional markets are likely to expand fastest?
Emerging markets in Asia-Pacific and Latin America, due to increasing healthcare access and aging populations.

Are there significant patent expirations affecting these drugs?
Aspirin patents expired in most markets by the early 2000s, leading to widespread generic adoption. Dipyridamole’s key formulations face no upcoming patent expiry.

What are the main risks to future revenue streams?
Adverse effects, competition from alternative therapies, and regulatory changes limiting indications or access.

---

References

[1] Grand View Research. (2022). Aspirin Market Size, Share & Trends Analysis Report.
[2] IQVIA. (2022). Medicine Usage and Market Share Reports.